HIPPOCRATES
HIPPOCRATES – Promoting Early Identification and Improving Outcomes in Psoriatic Arthritis
- Description
Psoriatic Arthritis (PsA) is a clinically heterogenous disease which is associated with a diminished quality of life. Early diagnosis is challenging and prediction of natural history or therapeutic response to treatment is suboptimal. This represents critical, contemporary unmet clinical needs.
By looking into the disease mechanisms of psoriatic arthritis, the 26 partners collaborating in the Horizon 2020 research project HIPPOCRATES aim at improving diagnostic and therapeutic options for patients living with this condition. Through gaining a better understanding of the complex interplay between clinical and environmental factors, genotype and molecular pathways, the team aims to enable earlier diagnosis and a more accurate prediction of disease progression. This will revolutionise treatment and deliver profound patient benefits.
The project budget of EUR 21 million is provided by the Innovative Medicines Initiative (IMI 2), a Joint Undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
It is the first Innovative Medicines Initiative (IMI2) project on PsA.
- Coordinator
Related News
- Programme
- Horizon 2020 & sub-programmes
- Duration
- 60 months (July 2021 - June 2026)
- Project funding
- € 21,245,992.00
- Project partners
- 28
- Project website
- https://hippocrates-imi.eu/
